Vingroup, a leading Vietnamese conglomerate, is redefining the role of business in society. Through a diverse portfolio and a deep commitment to social responsibility, they are actively cultivating an ecosystem that fosters positive social impact. HANOI, VIETNAM – Media OutReach Newswire – 20 September 2024 – In the wake of
VICTORIA, Seychelles, Sept. 20, 2024 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, proudly celebrates its 6th anniversary with a significant milestone — surpassing 45 million users worldwide, overtaking its competitors becoming the fourth largest crypto exchange by trading volume. The platform boasts as the fastest growing
VICTORIA, Seychelles, Sept. 20, 2024 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, proudly celebrates its 6th anniversary with a significant milestone — surpassing 45 million users worldwide, overtaking its competitors becoming the fourth largest crypto exchange by trading volume. The platform boasts as the fastest growing
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced that the underwriters of its previously announced upsized initial public offering of 13,235,294 shares of
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced that the underwriters of its previously announced upsized initial public offering of 13,235,294 shares of
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced that the underwriters of its previously announced upsized initial public offering of 13,235,294 shares of
